News Medical on MSN4d
Gene therapy breakthrough offers hope for severe Dravet syndrome casesAAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage ...
About Dravet Syndrome Stoke Therapeutics (Nasdaq ... not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be ...
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability ...
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...
Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.
Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.
“In 2024, we launched our ongoing POLARIS program evaluating ETX101 in SCN1A+ Dravet syndrome. With multiple dose levels administered, we expect to share preliminary efficacy data in the second ...
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback